LOS ANGELES, June 14, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against General Motors Company (“GM” or the “Company”) (NYSE:GM) for possible violations of federal securities laws between February 27, 2012 and May 25, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the July 26, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The Complaint states that throughout the Class Period, GM made false and/or misleading statements and/or failed to disclose: that GM installed three distinct defeat devices in over 700,000 trucks with Duramax diesel engines from 2011 to 2016, in order to beat emissions tests in the U.S.; that these Duramax diesel trucks emit two-to-five times the legal limit of nitrogen oxide pollutants; and thus, GM’s public statements were materially false and misleading at all relevant times. Upon release of this news, GM’s stock price fell materially, which harmed investors according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/


Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Washington Post Publisher Will Lewis Steps Down After Layoffs
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



